

Subject Screenings and testing for opioids

Authors Koegel

Analyst Larie Ann Pampuch

Date March 5, 2021

Overview

This bill prohibits health plan companies, Medical Assistance, and MinnesotaCare from placing a lifetime or annual limit on screenings or urinalysis testing for opioids.

Summary

Section	Description
---------	-------------

1	[62Q.472] Screening and testing for opioids.
---	---

(a) Prohibits a health plan company from placing a lifetime or annual limit on screenings or urinalysis testing for opioids for those in an inpatient or outpatient substance use disorder treatment program. Tests must be ordered by a health care provider and performed at an accredited clinical laboratory. Clarifies that a health plan company may perform a medical necessity review for an enrollee who exceeds 24 tests in any 12-month period.

(b) Clarifies that this section does not apply to managed care plans or county-based purchasing plans when the plan provides public health care coverage under chapters 256B or 256L.

Effective date. This section is effective January 1, 2022, and applies to health plans offered, issued, or renewed on or after that date.

2	Laboratory and x-ray services.
---	---------------------------------------

Requires medical assistance to cover screenings and urinalysis tests for opioids without lifetime or annual limits.

Effective date. This section is effective January 1, 2022.



**MN HOUSE
RESEARCH**

Minnesota House Research Department provides nonpartisan legislative, legal, and information services to the Minnesota House of Representatives. This document can be made available in alternative formats.

www.house.mn/hrd | 651-296-6753 | 155 State Office Building | St. Paul, MN 55155